# US 2021/0341467 A1 · Portable devices and methods for detecting and identifying compounds in saliva

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0341467 A1
- Document ID: US20210341467A1
- Status: Published application
- Kind: A1
- Application number: 16/933,525
- Filed: 2020-07-20
- Published: 2021-11-04
- Earliest claimed: 2020-05-04
- Assignees: Pelican Diagnostics Inc.
- Applicants: Pelican Diagnostics Inc.
- Inventors: Raj Reddy
- Web page: https://patentgrep.com/patent/US20210341467A1

## CPC

- G01N 33/54306: {Solid-phase reaction mechanisms}
- B01L 3/5023: {with a sample being transported to, and subsequently stored in an absorbent for analysis}
- B01L 3/5029: {using swabs}
- C12M 23/54: {hand portable}
- C12M 41/48: {Automatic or computerized control (automatic analysis G01N35/00)}
- G01N 33/5438: {Electrodes}
- G01N 33/56983: {Viruses}
- G01N 33/577: involving monoclonal antibodies {binding reaction mechanisms characterised by the use of monoclonal antibodies (G01N33/5302 - G01N33/576 take precedence)}
- B01L 2200/16: Reagents, handling or storing thereof
- B01L 2300/023: Sending and receiving of information, e.g. using Bluetooth®
- B01L 2300/027: Digital display, e.g. LCD, LED
- B01L 2300/0663: Whole sensors
- B01L 2300/0681: Filter
- B01L 2300/0825: Test strips
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- B01L: CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- C12M: APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; {APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS}

## Abstract

This disclosure relates to portable devices for SARS-COV-2 Antigen (SC2A), a biomarker for the detection of Coronavirus disease 2019 (COVID19). Diagnosis of viral infections such as SARS-COV-2 can be obtained in the early stages of a disease by detection of viral antigens (e.g., SC2A) directly in the clinical specimen.

## Claims

### Claim 1

A portable device for detecting and identifying antigen compounds in the saliva or antibodies in the blood of a subject comprising:
a. a biosensor connected to a device;
b. a sensor module disposed in a housing of the device, wherein the sensor module collects data, and thereby detects and identifies one or more antigen compounds and/or one or more antibody compounds in a saliva or blood sample;
c. a communication apparatus disposed to the sensor module, wherein the communication apparatus electrically transmits the collected data; and
d. a battery disposed to the communication apparatus and the sensor module.

### Claim 2 (depends on 1)

The portable device of claim 1, further comprising a processing apparatus electronically or wirelessly connected to the communication apparatus, wherein the processing apparatus processes the data transmitted by the communication apparatus to detect and identify the compound.

### Claim 3 (depends on 2)

The portable device of claim 2, wherein the processing apparatus transmits the identity of the compound detected in a sample from the processing apparatus to a display.

### Claim 4 (depends on 1)

The device of claim 1, further comprising an amplifier connected to the sensor module, wherein the amplifier amplifies data collected by the sensor module.

### Claim 5 (depends on 1)

The device of claim 1, wherein an antigen compound or antibody compound is detected in real time.

### Claim 6 (depends on 1)

The device of claim 1, wherein an antigen compound is immobilized with one or more nanoparticles, wherein the one or more nanoparticles include one or more marker compounds.

### Claim 7 (depends on 6)

The device of claim 6, wherein the antigen compound identified and detected is a marker compound.

### Claim 8 (depends on 7)

The device of claim 7, wherein the marker compound is functionalized or immobilized with graphene nanoplates and block co-polymer inorganic.

### Claim 9 (depends on 5)

The device of claim 5, wherein the antigen compound is a viral antigen.

### Claim 10 (depends on 9)

The device of claim 9, wherein the viral antigen is selected from the group consisting of SARS-COV-2 Antigen (SC2A), Immunoglobulin G (IgG), and anti-mitochondrial M2 (anti-M2).

### Claim 11 (depends on 9)

The device of claim 9, wherein the viral antigen is SC2A.

### Claim 12

A sensor comprising:
a. a gold coated interdigital electrode, wherein the interdigital electrode comprises a nanocomposite of graphene nanoplatelet with diblock-co-polymer, wherein the nanocomposite includes one or more immobilized antigen molecules; and
b. a support on which the electrodes are disposed.

### Claim 13

A method for detecting and identifying antigen compounds from a fluid sample of a subject comprising:
a. collecting and chemically treating a fluid sample of a subject;
b. collecting the sample in a connected device, wherein the device comprises a housing including at least a sensor module having at least one sensor, a communication apparatus, and a battery, wherein the at least one sensor comprises one or more electrodes and at least one antibody bound to the one or more electrodes via 3,3′-Dithiodipropionic acid (N-hydroxysuccinimide ester) (DTSP) —self-assembled-monolayer (SAM);
c. collecting data about the presence and identity of one or more antigen compounds with the sensor module, wherein a first antigen compound binds to the at least one antibody bound to the one or more electrodes;
d. communicating collected data via the communication apparatus to a processing apparatus; and
e. processing the communicated data to detect and identify the one or more antigen compounds, wherein the first antigen compound is identified as SARS-COV-2 antigen (SC2A).

### Claim 14 (depends on 13)

The method of claim 13, wherein a second antigen compound detected and identified is a viral antigen that is not SC2A.

### Claim 15 (depends on 14)

The method of claim 14, wherein the viral antigen is selected from the group consisting of IgG and anti-M2.

### Claim 16

(canceled)

### Claim 17 (depends on 13)

The method of claim 13, wherein the SC2A antigen is an indicator of the subject suffering from a SARS-COV-2 infection.

### Claim 18 (depends on 13)

The method of claim 13, wherein the one or more antigen compounds are detected at a concentration of about 40 fg/mL to 100 ng/mL.

### Claim 19 (depends on 13)

The method of claim 13, wherein the one or more antigen compounds are detected at a concentration of about 50 fg/mL to 10 ng/mL.

### Claim 20 (depends on 13)

The method of claim 13, wherein the collected data is converted to an electrical signal prior to communication to the processing apparatus.
